Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 December 2022 | Story André Damons | Photo Sonia Small
Dr Nicholas Pearce
Prof Nicholas Pearce has joined the Faculty of Health Sciences’ management team after being appointed Head of the School of Clinical Medicine. Prof Pearce is the former Head of the Department of Surgery at the UFS and led the Universitas Hospital’s COVID-19 Task Team.

During the height of the COVID-19 pandemic, Prof Nicholas Pearce led the COVID-19 Task Team of the Universitas Academic Hospital, ensuring that the hospital not only had enough Personal protective equipment (PPEs) and beds for patients, but also that the vaccination process ran smoothly. Now, the Best Doctor of the Year for 2022 – as named during this year’s National Annual Batho Pele Excellence Awards (NBPEA) – will lead the School of Clinical Medicine in the Faculty of Health Sciences at the University of the Free State (UFS).

Prof Pearce, former Head of the Department of Surgery at the UFS who served the faculty in multiple capacities over a long period, took up this position on 1 December 2022 – a position he is looking forward to.  

Create world-class doctors, maximise students’ full potential

“I’m excited about taking up my new position as Head of the School of Clinical Medicine. This is a role that comes with huge responsibility, and my vision is to create world-class doctors and to maximise each student’s full potential.  We, as university, are a national asset and need to grow and develop to be of service to the future of our country.  So, to lead a school with such a prestigious history is truly a privilege,” says Prof Pearce. 

According to him, the goal for the Medical School in the next five years should be determined by three main core drivers: service delivery, research, and teaching and training. He would like to be in a stronger position, with innovation that can produce world-class doctors (both undergraduate and postgraduate). 

If you look at the strategic plan of the UFS, says Prof Pearce, it is clear that, under the leadership of current Rector and Vice-Chancellor, Prof Francis Petersen, a period of regeneration and innovation is upon the university. Tied to this concept is the idea of self-evaluation and improvement. The idea of challenges and coming up with solutions excites him.  

“I think for a while, my main aim will be to bring the university, the provincial Department of Health, and the school in alignment, ensuring that we are all pulling in the same direction to achieve the same goal.”  

“At the end of the day, the goal here is to provide quality health care to the people of South Africa, while the Department of Health, the university, and society each function in different environments – coming together and understanding each other’s needs and having a common goal – excellent health care in this country for all our citizens.”

Lessons learned from surgery and running COVID-19 task teams

Prof Pearce, who was awarded the UFS Chancellor’s Medal for outstanding service during the April graduation ceremonies, says lessons learned from being both a surgeon and running COVID-19 task teams, are that strategic organisational processes need to be in place – systems strengthened, the policies and procedures adapted, and comprehensive planning taking place. 

However, he says, one must also bear in mind that we have a history of very high academic standards in the School of Clinical Medicine, so you want to improve on that rather than go backwards.

“I learned a lot from surgery and COVID-19 that will equip me in future. COVID-19 taught me about organisational management, disaster management, funding, resource management, people management skills, development, etc.  
“Running the Department of Surgery, one of the largest departments in the faculty with multiple inputs and personalities, has taught me that you are only as strong as the team behind you. I have an amazing team behind me in this new role, whether it is the dean, vice-dean, heads of department, administration, rectorate, and so forth.” 

He will continue to work at the Universitas Hospital; however, being fully employed by the university, he will only be doing some calls and working over weekends.  

“As a surgeon, theatre has always been my safe haven, my place of meditation, my place of peace, and I am sad to say goodbye to surgery and the Department of Surgery – it has been loyal, and I am grateful to everyone in the department; but I think as with all good things, there is a time to come and a time to go.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept